期刊文献+

卡马西平在癫痫患儿中的群体药动学研究 被引量:5

Study of Population Pharmacokinetics of Carbamazepine in Pediatric Patients with Epilepsy
原文传递
导出
摘要 目的:研究卡马西平(CBZ)在癫痫患儿中的群体药动学。方法:回顾性收集我院119例服用CBZ的门诊癫痫患儿的稳态血药浓度(n=122)。用非线性混合效应模型(NONMEM)法进行数据分析,定量考察年龄、性别、体重、日剂量和合用其他抗癫痫药对CBZ清除率的影响。采用一房室开放模型和一级吸收和消除的药动学模型,按照固定吸收速率常数文献值,最终求算CBZ的清除率。结果:最终拟合群体药动学模型为:CL=0.593·(体重/28.5)0.63·日剂量0.569。性别、合用丙戊酸钠不影响CBZ的清除率。结论:用NONMEM法估算CBZ的清除率和推荐剂量,可为临床制订个体化给药方案、提高疗效、降低药物的毒副作用提供依据。 OBJECTIVE:To investigate the population pharmacokinetics of carbamazepine (CBZ) in epileptic children.METHODS:Steady state serum concentrations data (n=122) were collected from 119 patients of our hospital during their routine clinical care.The effects of age,gender,body weight,daily dose and combined with other antiepileptic drugs on the clearance rate of CBZ were investigated by using Nonlinear mixed effect model (NONMEM),and the clearance rate of CBZ was calculated using a one-compartment model and first-order absorption and elimination pharmacokinetic model according to absorption rate constant.RESULTS:The final fitted pharmacokinetic model was:CL=0.593·(WT/28.5)0.63·(daily dose)0.569.Gender and combined with VPA didn't alter the CBZ clearance rate.CONCLUSION:NONMEM used to calculate clearance rate and recommended dose of CBZ can provide basis for the formulation of individual dosage regimen,efficacy improvement and toxicity effect reduction.
出处 《中国药房》 CAS CSCD 北大核心 2011年第30期2819-2821,共3页 China Pharmacy
基金 2010年深圳市科技计划项目(201003145)
关键词 儿童 卡马西平 群体药动学 非线性混合效应模型 Children Carbamazepine Population pharmacokinetics Nonlinear mixed effect model
  • 相关文献

参考文献7

  • 1Sheiner LB, Rosenberg B, Marathe VV.Estimation of population characteristics of pharmacokinetic parameters from routine elinieal date[J].Pharmaeokinet Biopharm, 1997,25(2) :445.
  • 2Yukawa E, Aoyama T. Detection of Carbamazepine Drug Interaction by multiple peak approach screening using routine clinical pharmacokinetic data[J].Clin Pharmacol, 1996,36(9) : 752.
  • 3Hartley R, Forsythe WI, Mclain B, et al. Daily variation in steady state plasma concentrations of carbamazepine and its metabolites in epileptic children[J]. Clin Pharmacokinet, 1991,20(3) : 237.
  • 4Efron B, Tibshirani RJ. An Introduction to the Bootstrap [M].London: Chapman & Hall. 1993.
  • 5Efron B, Gong G.A leisurely look at the bootstrap.The jackknife, and cross-validation[J]~/m Star, 1983,37 ( 1 ) : 36.
  • 6焦正,钟明康,施孝金,胡敏,李中东,王大猷,张莉莉,张静华,王宏图.NONMEM法估算中国癫痫患者卡马西平的清除率[J].中国药理学通报,2003,19(3):314-318. 被引量:11
  • 7王刚,刘彬,黄晓英,杜彪,杨丽春.非线性混合效应模型法研究卡马西平在癫痫儿童中的群体药动学[J].中国医院药学杂志,2007,27(7):1001-1004. 被引量:10

二级参考文献34

  • 1[1]Bertilsson L,Tomson T. Clinical Pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. A update. Clin Pharmacokinet, 1986;11(3):197~8
  • 2[2]Guidance for Industry population pharmacokinetics. Feb 1999, FDA, http://www.fda.gov/ohrms/dockets/98fr/970383gd.pdf. 2001-12-30 last visited
  • 3[4]Wade JR, Kelman AW, Howie CA et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. Journal of pharmacokinetics and biopharmaceutics, 1993;2(21):209~22
  • 4[6]Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol, 1996;36(8):752~9
  • 5[7]Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono- and polytherapy. Eur J Clin Pharmacol, 1998;54(4):359~62
  • 6[8]Graves NM, Brundage RC, Wen Y et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy, 1998;18(2):273~81
  • 7[9]Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol, 2001;51(6):567~76
  • 8[10]Delgado-Iribarnegarary MF, Santos-Buelga D, Garcia-Sanchez MJ et al. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit, 1997;19(2):132~9
  • 9[11]Reith DM, Hooper WD, Parke J, Charles B. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Biopharm, 2001;28(1):79~92
  • 10[12]Vozeh S, Maitre OP, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm, 1990;28(2):161~73

共引文献16

同被引文献51

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部